Tokyo Tape
Sign in
← Taiko Pharmaceutical

Half-year report · Q2

4574.TEDINET S100U6M9
Period2024-01-01 → 2024-06-30
Filed2024-08-09
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥2.9bn2024-01-01 → 2024-06-30Cons.Net sales
Revenue¥6.1bn2023-01-01 → 2023-12-31Cons.Net sales (5-year summary)
Revenue¥2.5bn2023-01-01 → 2023-06-30Cons.Net sales
Operating income¥482m2024-01-01 → 2024-06-30Cons.Operating income
Operating income−¥396m2023-01-01 → 2023-06-30Cons.Operating income
Ordinary income¥528m2024-01-01 → 2024-06-30Cons.Ordinary income
Ordinary income−¥1.2bn2023-01-01 → 2023-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥510m2023-01-01 → 2023-06-30Cons.Ordinary income
Profit before tax¥724m2024-01-01 → 2024-06-30Cons.Income before income taxes
Profit before tax−¥492m2023-01-01 → 2023-06-30Cons.Income before income taxes
Net income (owners)¥764m2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥3.6bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥514m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income¥764m2024-01-01 → 2024-06-30Cons.Profit loss
Net income−¥514m2023-01-01 → 2023-06-30Cons.Profit loss
Total assets¥13.4bnat 2024-06-30Cons.Assets
Total assets¥13.2bnat 2023-12-31Cons.Assets
Total assets¥15.6bnat 2023-06-30Cons.Total assets (5-year summary)
Total liabilities¥5.3bnat 2024-06-30Cons.Liabilities
Total liabilities¥6.5bnat 2023-12-31Cons.Liabilities
Net assets / equity¥8.1bnat 2024-06-30Cons.Net assets
Net assets / equity¥6.7bnat 2023-12-31Cons.Net assets
Net assets / equity¥9.2bnat 2023-06-30Cons.Net assets (5-year summary)
Cash and deposits¥5.2bnat 2024-06-30Cons.Cash and deposits
Cash and deposits¥5.5bnat 2023-12-31Cons.Cash and deposits
Cash & equivalents¥4.9bnat 2024-06-30Cons.Cash and cash equivalents
Cash & equivalents¥5.2bnat 2023-12-31Cons.Cash and cash equivalents
Cash & equivalents¥4.5bnat 2023-06-30Cons.Cash and cash equivalents
Cash & equivalents¥2.8bnat 2022-12-31dCons.Cash and cash equivalents
Operating cash flow¥256m2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥307m2023-01-01 → 2023-12-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥126m2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥135m2024-01-01 → 2024-06-30Cons.Net cash provided by used in investment activities
Investing cash flow¥1.2bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow¥707m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥562m2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities
Financing cash flow¥1.5bn2023-01-01 → 2023-12-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥827m2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥15.242024-01-01 → 2024-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-76.252023-01-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-11.362023-01-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio60.3%at 2024-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio51.0%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio58.7%at 2023-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Otherother segmentsrevenue2024-01-01 → 2024-06-30¥2m
Otherother segmentsrevenue external2024-01-01 → 2024-06-30¥2m
Otherother segmentssegment profit2024-01-01 → 2024-06-30−¥6m
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-06-30−¥401m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥203m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥203m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥195m
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥2.7bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥2.7bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-06-30¥1.1bn
Total Of Reportable Segments And Otherssegment totalrevenue2024-01-01 → 2024-06-30¥2.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-01-01 → 2024-06-30¥2.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-01-01 → 2024-06-30¥884m
Otherother segmentsrevenue2023-01-01 → 2023-06-30¥2m
Otherother segmentsrevenue external2023-01-01 → 2023-06-30¥2m
Otherother segmentssegment profit2023-01-01 → 2023-06-30−¥11m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-06-30−¥492m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥370m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥370m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥407m
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥2.1bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥2.1bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥514m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-06-30¥2.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-06-30¥2.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-06-30¥95m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 518
ItemContextValueUnit
Other noiPrior1YTDDuration3000000JPY
Other noiCurrentYTDDuration10000000JPY
Non operating incomePrior1YTDDuration51000000JPY
Non operating incomeCurrentYTDDuration63000000JPY
Interest expenses noePrior1YTDDuration4000000JPY
Interest expenses noeCurrentYTDDuration4000000JPY
Rent expenses noePrior1YTDDuration0JPY
Rent expenses noeCurrentYTDDuration4000000JPY
Plant shutsdown related costs noePrior1YTDDuration145000000JPY
Plant shutsdown related costs noeCurrentYTDDuration－JPY
Commission fee noePrior1YTDDuration15000000JPY
Commission fee noeCurrentYTDDuration6000000JPY
Other noePrior1YTDDuration0JPY
Other noeCurrentYTDDuration2000000JPY
Non operating expensesPrior1YTDDuration165000000JPY
Non operating expensesCurrentYTDDuration18000000JPY
Ordinary incomePrior1YTDDuration-510000000JPY
Ordinary incomeCurrentYTDDuration528000000JPY
Gain on sales of investment securities eiPrior1YTDDuration87000000JPY
Gain on sales of investment securities eiCurrentYTDDuration－JPY
Compensation income eiPrior1YTDDuration－JPY
Compensation income eiCurrentYTDDuration200000000JPY
Extraordinary incomePrior1YTDDuration87000000JPY
Extraordinary incomeCurrentYTDDuration200000000JPY
Impairment loss elPrior1YTDDuration69000000JPY
Impairment loss elCurrentYTDDuration－JPY
Loss on valuation of investment securities elPrior1YTDDuration－JPY
Loss on valuation of investment securities elCurrentYTDDuration4000000JPY
Extraordinary lossPrior1YTDDuration69000000JPY
Extraordinary lossCurrentYTDDuration4000000JPY
Income before income taxesPrior1YTDDuration-492000000JPY
Income before income taxesCurrentYTDDuration724000000JPY
Income taxes currentPrior1YTDDuration7000000JPY
Income taxes currentCurrentYTDDuration27000000JPY
Income taxes deferredPrior1YTDDuration14000000JPY
Income taxes deferredCurrentYTDDuration-68000000JPY
Income taxesPrior1YTDDuration22000000JPY
Income taxesCurrentYTDDuration-40000000JPY
Profit lossPrior1YTDDuration-514000000JPY
Profit lossCurrentYTDDuration764000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration-514000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration764000000JPY
Profit lossPrior1YTDDuration-514000000JPY
Profit lossCurrentYTDDuration764000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration119000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration378000000JPY
Foreign currency translation adjustment net of tax ociPrior1YTDDuration60000000JPY
Foreign currency translation adjustment net of tax ociCurrentYTDDuration113000000JPY
Other comprehensive incomePrior1YTDDuration180000000JPY
Other comprehensive incomeCurrentYTDDuration492000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net assetsconsolidated 2024-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-06-30pass